Out-of-Hospital Noninvasive Ventilation: Epidemiology, Technology and Equipment

Baird, John Scott; Ravindranath, Thyyar

doi:10.4081/pr.2012.e17

Cited by 9 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27,28 Commonly reported complications of NIV include aspiration pneumonia, gastric distension, vomiting, pressure lesions or sores, interface device leaks, intolerance to NIV and ventilator asynchrony. 29 Non-invasive ventilation modes or modalities have been described in different ways. 30 The ventilatory mode may be defined according to the method of gas flow administration.…”

Section: Description Of the Technology Under Assessmentmentioning

confidence: 99%

Section: Description Of the Technology Under Assessmentmentioning

confidence: 99%

“…29,31 This mode is suitable for patients who are breathing spontaneously because it can only provide support to an underlying respiratory drive. 29,31,32 CPAP improves ventilation-perfusion matching and thereby improves oxygenation. 29 Other physiological effects of this mode of NIV include a reduction in venous return and a decrease in left ventricular wall stress; both effects result in an improvement in cardiac output.…”

Section: Description Of the Technology Under Assessmentmentioning

confidence: 99%

“…29,31,32 CPAP improves ventilation-perfusion matching and thereby improves oxygenation. 29 Other physiological effects of this mode of NIV include a reduction in venous return and a decrease in left ventricular wall stress; both effects result in an improvement in cardiac output. 29 This is particularly important in patients with acute cardiogenic pulmonary oedema (ACPO).…”

Section: Description Of the Technology Under Assessmentmentioning

confidence: 99%

“…29 Other physiological effects of this mode of NIV include a reduction in venous return and a decrease in left ventricular wall stress; both effects result in an improvement in cardiac output. 29 This is particularly important in patients with acute cardiogenic pulmonary oedema (ACPO). There is no recommended initial pressure setting for CPAP; however, this may be determined by the patient's age and the nature and severity of underlying disease.…”

Section: Description Of the Technology Under Assessmentmentioning

confidence: 99%

See 4 more Smart Citations

Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation

Pandor

Thokala

Goodacre

et al. 2015

Health Technol Assess

View full text Add to dashboard Cite

BackgroundNon-invasive ventilation (NIV), in the form of continuous positive airway pressure (CPAP) or bilevel inspiratory positive airway pressure (BiPAP), is used in hospital to treat patients with acute respiratory failure. Pre-hospital NIV may be more effective than in-hospital NIV but requires additional ambulance service resources.ObjectivesWe aimed to determine the clinical effectiveness and cost-effectiveness of pre-hospital NIV compared with usual care for adults presenting to the emergency services with acute respiratory failure and to identify priorities for future research.Data sourcesFourteen electronic databases and research registers (including MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE, EMBASE, and Cumulative Index to Nursing and Allied Health Literature) were searched from inception to August 2013, supplemented by hand-searching reference lists and contacting experts in the field.Review methodsWe included all randomised or quasi-randomised controlled trials of pre-hospital NIV in patients with acute respiratory failure. Methodological quality was assessed according to established criteria. An aggregate data network meta-analysis (NMA) of mortality and intubation was used to jointly estimate intervention effects relative to usual care. A NMA, using individual patient-level data (IPD) and aggregate data where IPD were not available, was carried out to assess whether or not covariates were treatment effect modifiers. A de novo economic model was developed to explore the costs and health outcomes when pre-hospital NIV (specifically CPAP provided by paramedics) and standard care (in-hospital NIV) were applied to a hypothetical cohort of patients with acute respiratory failure.ResultsThe literature searches identified 2284 citations. Of the 10 studies that met the inclusion criteria, eight were randomised controlled trials and two were quasi-randomised trials (six CPAP; four BiPAP; sample sizes 23–207 participants). IPD were available from seven trials (650 patients). The aggregate data NMA suggested that CPAP was the most effective treatment in terms of mortality (probability = 0.989) and intubation rate (probability = 0.639), and reduced both mortality [odds ratio (OR) 0.41, 95% credible interval (CrI) 0.20 to 0.77] and intubation rate (OR 0.32, 95% CrI 0.17 to 0.62) compared with standard care. The effect of BiPAP on mortality (OR 1.94, 95% CrI 0.65 to 6.14) and intubation rate (OR 0.40, 95% CrI 0.14 to 1.16) compared with standard care was uncertain. The combined IPD and aggregate data NMA suggested that sex was a statistically significant treatment effect modifier for mortality. The economic analysis showed that pre-hospital CPAP was more effective and more expensive than standard care, with an incremental cost-effectiveness ratio of £20,514 per quality-adjusted life-year (QALY) and a 49.5% probability of being cost-effective at the £20,000-per-QALY threshold. Variation in the incidence of eligible patients had a marked impact on cost-effectiveness and the expected value of sample information for a future randomised trial.LimitationsThe meta-analysis lacked power to detect potentially important differences in outcome (particularly for BiPAP), the intervention was not always compared with the best alternative care (in-hospital NIV) in the primary studies and findings may not be generalisable.ConclusionsPre-hospital CPAP can reduce mortality and intubation rates, but cost-effectiveness is uncertain and the value of further randomised evaluation depends on the incidence of suitable patients. A feasibility study is required to determine if a large pragmatic trial of clinical effectiveness and cost-effectiveness is appropriate.Study registrationThe study is registered as PROSPERO CRD42012002933.FundingThe National Institute for Health Research Health Technology Assessment programme.

show abstract

Section: Description Of the Technology Under Assessmentmentioning

confidence: 99%